araag2/HINT huggingface dataset:
Clinical trial NCT00462852 (phase 2, status: completed)
Conditions: pancreatic cancer, thromboembolism
ICD codes: C25.3, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dalteparin, gemcitabine hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed metastatic or locally advanced
             adenocarcinoma of the pancreas

               -  Patients with clinical 'high probability' of pancreatic cancer and biopsy
                  suggestive but not diagnostic of pancreatic cancer may be eligible based on
                  review by the principal investigator

          -  Measurable or evaluable disease

          -  No clinical evidence of active venous thromboembolism

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) 60-100% OR WHO PS 0-2

          -  Life expectancy > 12 weeks

          -  Absolute neutrophil count > 2,000/mm³

          -  WBC > 3,000/mm³

          -  Platelet count > 100,000/mm³

          -  Creatinine clearance > 50 mL/min

          -  INR ≤ 1.5 times upper limit of normal (ULN)

          -  Bilirubin < 1.5 times ULN (stent allowed)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No cerebrovascular accident within the past 6 months

          -  No obvious contraindication to anticoagulation, including the following:

               -  Bleeding diathesis

               -  Active peptic ulcer

               -  Ulcerating cancer into duodenum

          -  No history of other advanced malignancy

          -  No gross hematuria

          -  No melaena or gross evidence of gastrointestinal bleeding (other than piles)

          -  No requirement for a central line

          -  No other significant medial or psychiatric illness that, in the opinion of the
             investigator, would preclude study participation

        PRIOR CONCURRENT THERAPY:

          -  No prior gemcitabine hydrochloride-containing treatment

          -  No other concurrent cytotoxic chemotherapy, immunotherapy, hormonal therapy (excluding
             contraceptives and replacement steroids), or experimental medications

          -  No other concurrent specific anticancer therapy as a result of disease progression

          -  No concurrent caval filter device

          -  No other concurrent anticoagulants for venous thromboembolism or other reasons (e.g.,
             atrial fibrillation)

          -  No concurrent acetylsalicylic acid (> 75 mg) as an antiplatelet drug for a preexisting
             cardiovascular condition

          -  No concurrent clopidogrel bisulfate
Clinical trial NCT00603512 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, cp-690,550, cp-690,550, cp-690,550, cp-690,550
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  Active rheumatoid arthritis

          -  Inadequate response to stably dosed methotrexate

        Exclusion Criteria:

          -  Current therapy with any DMARD or biologic other than methotrexate
Clinical trial NCT00111943 (phase 2, status: completed)
Conditions: hiv infections, hepatitis b, chronic
ICD codes: Z21, B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: 1% tenofovir gel
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV uninfected

          -  Good general health

          -  Sexually active

          -  Willing to use acceptable methods of contraception, including male latex condoms for
             all acts of intercourse

          -  Willing to undergo all study-related assessments and adhere to the requirements of the
             study

        Exclusion Criteria:

          -  Menopausal or postmenopausal

          -  Hysterectomy

          -  Abnormal screening results for several gynecologic exams

          -  Taking or planning to take tenofovir, adefovir, or any other medication for chronic
             HBV infection

          -  History of latex allergy

          -  History of adverse reaction to tenofovir or adefovir

          -  Use of a diaphragm or spermicide for contraception

          -  Prior participation in the study

          -  Prior participation in any vaginal microbicide, spermicide, or other drug study within
             30 days of study entry

          -  Gynecologic surgical procedure within 90 days of study entry

          -  Illicit injection drug use within 12 months of study entry

          -  History of vaginal intercourse more than an average of two times per day in the two
             weeks prior to study screening

          -  Any other criteria that, in the investigator's opinion, may interfere with the study

          -  Current pregnancy or previous pregnancy within 90 days of study entry

          -  Breastfeeding
Clinical trial NCT00272207 (phase 2, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: nabilone
SMILES: [H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC
Eligibility criteria:

        Inclusion Criteria:

          -  The patient meets The American College of Rheumatology (1990) criteria for the
             classification of fibromyalgia. [5]

          -  18-70 years old.

          -  Any gender.

          -  The patient has not received benefit from a tricyclic antidepressant, muscle relaxant,
             acetaminophen or non-steroidal anti-inflammatories for management of their pain.

          -  No previous use of oral cannabinoids for pain management.

        Exclusion Criteria:

          -  The patient's pain is better explained by a diagnosis other then fibromyalgia.

          -  Abnormalities on routine baseline blood work including electrolytes, urea and
             creatinine, a complete blood count, and liver function tests (AST ALT GGT, Alk Phos,
             and LDH). Normal tests taken within 3 months prior to the study will be accepted if
             there is no history of acute illness since the time the blood was drawn.

          -  Heart disease. (Cannabinoids can reduce heart rate and blood pressure) Patients with
             heart disease will be excluded based on a history of angina, MI or CHF as well as a
             clinical exam.

          -  Schizophrenia or other Psychotic disorder

          -  Severe liver dysfunction. (Patients will be excluded if there is an elevation of any
             of the baseline liver enzymes)

          -  History of untreated non-psychotic emotional disorders.

          -  Cognitive impairment.

          -  Major illness in another body area.

          -  Pregnancy.

          -  Nursing mothers.

          -  Patients less than 18 years old.

          -  History of drug dependency.

          -  A known sensitivity to marijuana or other cannabinoid agents
Clinical trial NCT00128830 (phase 2, status: completed)
Conditions: human immunodeficiency virus type 1
ICD codes: D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822
Drugs: etravirine (etr), nucleotide reverse transcriptase inhibitors (nrtis), protease inhibitors (pis), enfuvirtide (enf)
SMILES: CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N, CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who were previously randomized to an etravirine (ETR) treatment arm and
             have completed at least 48 weeks of treatment with ETR

          -  Participants who will be able to comply with the protocol requirements

          -  Participants general medical condition should not interfere with the assessments and
             the completion of the study

        Exclusion Criteria:

          -  Use of disallowed concomitant therapy unless a prior exemption had been granted

          -  Participant with any treatment-emergent condition or exacerbation of underlying
             condition during original Phase II study

          -  Agrees to protocol-defined use of effective contraception

          -  Participant with a grade 3 elevation of amylase and/or lipase except for isolated
             grade 3 increases of amylase with lipase in normal range and no history of
             pancreatitis

          -  Participant with any grade 4 toxicity according to the Division of Acquired
             Immunodeficiency Syndrome (DAIDS) grading table; with the exception of grade 4
             elevations of triglycerides or glucose asymptomatic or under non-fasting conditions;
             grade 4 elevation of glucose in participants with pre-existing diabetes

          -  Participants with clinical or laboratory evidence of significantly decreased hepatic
             function or decompensation, irrespective of liver enzyme levels (International
             Normalized Ratio [INR] more than 1.5 or albumin less than 30g/l or bilirubin more than
             2.5 x upper limit of normal)
Clinical trial NCT01303224 (phase 2, status: completed)
Conditions: irritable bowel syndrome with diarrhea
ICD codes: K58.0, K58.9
Drugs: ibodutant, ibodutant, ibodutant, placebo
SMILES: CC1=CC=C2C=C(SC2=C1)C(=O)NC1(CCCC1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC1CCN(CC2CCOCC2)CC1, CC1=CC=C2C=C(SC2=C1)C(=O)NC1(CCCC1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC1CCN(CC2CCOCC2)CC1, CC1=CC=C2C=C(SC2=C1)C(=O)NC1(CCCC1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NCC1CCN(CC2CCOCC2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        At start of the run-in period:

          -  Male or female patients aged 18 - 70 years with a clinical diagnosis of IBS-D
             according to the Rome III criteria:

          -  Recurrent abdominal pain/discomfort for at least 3 days per month in the last 3 months
             associated with at least 2 of the following characteristics:

               1. improvement with defecation;

               2. onset associated with a change in the frequency of stool;

               3. onset associated with a change in form (appearance) of stool.

          -  Symptom-onset at least 6 months prior to diagnosis.

          -  Loose/watery stools at least 25% of the time in the last 3 months AND hard/lumpy
             stools less than 25% of the time in the last 3 months.

          -  More than 3 bowel movements per day at least 25% of the time in the last 3 months.

          -  For patients older than 50 years OR patients with positive family history of
             colorectal cancer: Normal results from colonoscopy or flexible sigmoidoscopy.

          -  Mentally competent, able to give written informed consent.

          -  For women of childbearing potential: Use of a highly effective contraceptive method
             throughout the entire study period and up to 30 days post-treatment.

          -  Normal physical examination or without clinically relevant abnormalities.

        At randomisation:

        -Confirmation of IBS-D severity in terms of bowel movement frequency and abdominal pain
        intensity along the 2-week run-in period.

        Exclusion criteria:

          -  Organic abnormalities of the gastrointestinal tract, including history of colonic or
             major abdominal surgery.

          -  History of gluten enteropathy.

          -  Lactose intolerance as assessed by response to diet.

          -  History of positive tests for ova or parasites, or occult blood in the stool.

          -  Previous diagnosis of diabetes mellitus (either type 1 or 2).

          -  Unstable medical condition.

          -  Major psychiatric, neurological, or cardiovascular disorders, or uncontrolled
             metabolic disease.

          -  Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2
             months.

          -  Use of concurrent medication with drugs known to interfere with gastro-intestinal
             motility or sensitivity.

          -  Pregnancy or breastfeeding.
Clinical trial NCT00358644 (phase 2, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          1. A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks
             of study enrollment.

          2. Ineligible to receive intensive chemotherapy for their disease.

          3. Have not received any chemotherapy within 4 weeks of study enrollment and must have
             recovered from any treatment-related toxicities.

        Exclusion Criteria:

          1. Received previous treatment for AML.

          2. Previously received Vidaza.

          3. Received any other investigational agents within 30 days of first dose of study drug.

          4. Uncontrolled intercurrent illness.

          5. Had radiotherapy within 14 days prior to study enrollment.
Clinical trial NCT00633789 (phase 2, status: completed)
Conditions: advanced non-small cell lung cancer, transitional cell carcinoma, soft tissue sarcoma, gastric/esophageal adenocarcinoma, pancreatic cancer including ampulla of vater
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, C46.1
Drugs: brivanib, placebo
SMILES: C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For additional information, please contact the BMS oncology clinical trial information
        service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
        www.BMSStudyConnect.com for more information on clinical trial participation.

        Inclusion Criteria:

          -  Life expectancy at least 3 months

          -  Diagnosis of a solid tumor which is unresectable in which no approved effective
             therapy exists or for subjects who are intolerable to such therapy. The initial
             enrollment will focus on non-small cell lung, gastric/esophageal adenocarcinoma, soft
             tissue sarcoma, transitional cell carcinoma, and pancreatic cancer including ampulla
             of Vater tumors

          -  Adequate tumor sample

          -  Adequate recovery (baseline or Grade 1) from recent therapy. At least 1 week must have
             elapsed from the time of a minor surgery, and at least 8 weeks for major surgery or
             radiation therapy

        Exclusion Criteria:

          -  Subjects with known brain metastasis.

          -  Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless
             brain metastases are ruled out by CT or MRI

        Medical History and Concurrent Diseases:

          -  History of thrombo-embolic disease within the last six months requiring therapeutic
             anticoagulation

          -  Subjects with history of poor wound healing or non healing ulcers

          -  Uncontrolled or significant cardiovascular disease

        Allergies and Adverse Drug Reactions:

          -  History of allergy to brivanib its drug class, or related compounds

        Prohibited Treatments and/or Therapies:

          -  Exposure to any investigational drug within 4 weeks of enrollment

          -  Other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or
             radiotherapy, standard or investigational. Subjects may continue to receive hormone
             replacement therapy

          -  Prior exposure to brivanib
Clinical trial NCT00460551 (phase 2, status: terminated)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: induction chemotherapy
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Reason stopped: 
    due to considerations regarding the appropriate therapeutic regimen for these patients.
  
Eligibility criteria:

        Inclusion Criteria:

          -  NSCLC stage IIIA-IIIB

          -  Performance status 0 or 1 (Zubrod or WHO Scale)

        Exclusion Criteria:

          -  Evidence of metastases either in a separate lobe of the lung, or extra thoracic

          -  Patients with high risk of radiation pneumonitis and or compromised lung function

          -  Estimated life expectancy of less than 3 months

          -  Prior chemotherapy for lung cancer

          -  Prior radiotherapy to the chest

          -  Prior surgery with curative intent for lung cancer
Clinical trial NCT00707746 (phase 2, status: completed)
Conditions: metabolic diseases, hyperlipidemias, metabolic disorder, hypercholesterolemia, dyslipidemias, lipid metabolism disorders
ICD codes: Z86.39, O99.280, O99.281, O99.282, O99.283, O99.284, O99.285, E88.9, O03.33, O04.83, O03.83, O07.33, E88.89, E89.89, E78.01, E78.00, Z83.42, Z83.438
Drugs: mipomersen, placebo
SMILES: [H]C1(CC([H])(OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C3NC(=N)N=C4O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C(N)N=CN=C34)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=NC3=C2NC(=N)N=C3O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)C([H])(COP(O)(=S)OC2([H])CC([H])(OC2([H])COP(O)(=S)OC2([H])C([H])(COP(O)(=S)OC3([H])C([H])(COP(O)(=S)OC4([H])C([H])(COP(O)(=S)OC5([H])C([H])(COP(O)(=S)OC6([H])C([H])(CO)OC([H])(N7C=NC8=C7NC(=N)N=C8O)C6([H])OCCOC)OC([H])(N6C=C(C)C(=N)N=C6O)C5([H])OCCOC)OC([H])(N5C=C(C)C(=N)N=C5O)C4([H])OCCOC)OC([H])(N4C=C(C)C(O)=NC4=O)C3([H])OCCOC)OC([H])(N3C=C(C)C(=N)N=C3O)C2([H])OCCOC)N2C=NC3=C(N)N=CN=C23)O1)N1C=NC2=C1NC(=N)N=C2O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of statin intolerance

          -  Diagnosis of Coronary Artery Disease (CAD)

          -  Diagnosis of hypercholesterolemia

          -  Stable weight for > 6 weeks

        Exclusion Criteria:

          -  Significant health problems in the recent past (≤24 weeks) including heart attack,
             heart surgery, heart failure, uncontrolled hypothyroidism, blood disorders, digestive
             problems, disease of central nervous system, cancer, liver or renal disease
Clinical trial NCT00402181 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma with relapsed or refractory disease after
             failing at least 2 prior lines of therapy

          -  Prior treatment regimen must have included bortezomib (alone or in combination with
             other agents)

          -  Measurable secretory disease defined as either serum monoclonal paraprotein (M-
             protein) greater than or equal to (>=) 1 gram per deciliter (g/dL) or urine monoclonal
             (light chain) protein (greater than (>) 200 milligram/24 hours)

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of less than or
             equal to (<=) 2 - Participants of childbearing potential must use adequate birth
             control measures, female participants of childbearing potential must have a negative
             serum pregnancy test at screening

        Exclusion Criteria:

          -  Treatment with systemic cancer therapy (including clarithromycin) or radiotherapy
             within 30 days before the first dose of study agent - Treatment with nitrosoureas (a
             group of alkylating agents used as antineoplastic drugs in the chemotherapy) within 42
             days before the first dose of study agent

          -  Major surgery within 30 days before the first dose of study agent or planning to have
             surgery (except for minor surgical procedures) during the study

          -  Serious concurrent illness (medical or psychiatric), uncontrolled infection, or
             significant cardiac disease characterized by significant ischemic coronary disease (an
             imbalance between myocardial functional requirements and the capacity of the coronary
             vessels to supply sufficient blood flow) or congestive heart failure (condition in
             which the heart is unable to pump out sufficient blood to meet the metabolic need of
             the body) not under medical control, or any uncontrolled medical condition (for
             example: uncontrolled diabetes), including the presence of clinical laboratory
             abnormalities, that places the subject at unacceptable risk by participating in the
             study or confounds the ability to interpret data from the study

          -  Known to be seropositive (giving a positive result in a test of blood serum) for Human
             Immunodeficiency Virus (HIV), or active hepatitis A, B or C infection
Clinical trial NCT00550446 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: adalimumab, cp-690-550, cp-690-550, cp-690-550, cp-690,550, cp-690,550, placebo
SMILES: O, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have active rheumatoid arthritis

          -  Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)

          -  Subjects must not be currently taking any DMARD other than an antimalarial

        Exclusion Criteria:

          -  Subjects who discontinued any previous TNF inhibitor therapy for either lack of
             benefit or safety.

          -  Subjects who previously received adalimumab (Humira®) therapy for any reason.

          -  Subjects with evidence of blood disorders, chronic infections or untreated
             tuberculosis